baber/WOPTO huggingface dataset:
Patent NZ-560811-A (NZ)
Title: Heterocyclylamide-substituted imidazoles for use against viral infections such as Herpes
Inventor: ZIMMERMANN HOLGER
IPC: A61P31/12
Filed: 2006-02-14
Abstract: Disclosed is a compound of formula (I), or a salt or solvate thereof, wherein R1 is a group selected from the two nitrogen-containing rings shown, R2 is optionally substituted C1-6alkyl, R3 is optionally substituted phenyl, R4 is optionally substituted phenyl or 5-6 membered heteroaryl, and the other substituents are as defined in the specification. Also disclosed is a method for preparing the above compound, and the use of the compound for treating viral infections such as the human cytomegalovirus (HCMV).
Patent NZ-562194-A (NZ)
Title: Respiratory mask assembly with magnetic coupling to headgear assembly
Inventor: GING ANTHONY MICHAEL
IPC: A62B18/08
Filed: 2006-03-16
Abstract: A respiratory mask assembly for delivering breathable gas to a patient includes a frame (420) and a headgear assembly (480) which are adapted to being remove ably magnetically coupled to one another at a desired angular orientation therebetween.
Patent NZ-562929-A (NZ)
Title: Immunisation against chlamydia trachomatis
Inventor: GRANDI GUIDO
IPC: A61K48/00
Filed: 2002-12-12
Abstract: Disclosed is the use of a protein comprising an amino acid sequence as set forth in SEQ ID NO: 229, or a protein comprising an amino acid sequence having 70% or greater sequence identity to the amino acid sequence of SEQ ID NO: 229, or a protein comprising a fragment of at least seven contiguous amino acids of the sequence of SEQ ID NO: 229 in the manufacture of a medicament for the treatment or prevention of infection due to Chlamydia trachomatis.
Patent NZ-565981-A (NZ)
Title: Octagonal bulk bin constructed from a single blank with self-locking webbed bottom flats
Inventor: WISECARVER MARK
IPC: B65D5/02
Filed: 2006-08-29
Abstract: An octagonal bulk bin (10) erected from a blank is disclosed. The bin (10) has sidewalls (11, 12), end walls (13, 14) and diagonal corner panels (15, 16, 17, 18) interposed between adjacent sidewalls and end walls. Major bottom flaps (22, 23) are joined to a bottom edge of the sidewalls. Bottom flaps are joined to the bottom edge of the walls and panels that inter connect to form the bottom of the bin (10). Anti-tear cuts are formed in the bottom flaps joined to the sidewalls (11, 12) and foldable web panels interconnect opposite edges of bottom the flaps joined to the end walls (13, 14).
Patent NZ-573212-A (NZ)
Title: CRYSTALLINE DULOXETINE HYDROCHLORIDE Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine
Inventor: JIANG WEI PING
IPC: A61P25/00
Filed: 2007-06-21
Abstract: Disclosed is a method for the preparation of crystalline duloxetine hydrochloride, which has the systematic name, (+)-(S)-N-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine, the method for preparation comprising (a) dissolving duloxetine in a first organic solvent to form a first solution; (b) combining the first solution with a second organic solvent solution comprising HCl to form a second solution; (c) adding the second solution to a third organic solvent to form a third solution; (d) allowing duloxetine hydrochloride to crystallize out from the solution during a period of cooling at 0 - 10 degrees; and (e) collecting the crystallized duloxetine hydrochloride, wherein the first organic solvent is dichloromethane, the second organic solvent is ethanol and the third organic solvent is hexane. Also disclosed is crystalline duloxetine hydrochloride which exhibits an X-ray diffraction pattern comprising peaks expressed in degrees two-theta at approximately 11.95, 13.93, 14.5, 14.76, 16.19, 17.97, 18.62, 18.82, 20.79, 21.26, 21.44, 21.76, 22.12, 22.28, 23.08, 23.28, 24.06, 26.31, 26.94 and 29.86, plus or minus 0.2 for each value.
Patent NZ-576081-A (NZ)
Title: Anti-cd20 antibodies and methods of use
Inventor: SMITH ERNEST S
IPC: C12N5/0781
Filed: 2007-10-10
Abstract: Disclosed is an immunoglobulin that specifically binds CD20. Also disclosed are nucleic acid sequences encoding the immunoglobulin. The disclosed immunoglobulins are used to treat cancers and autoimmune or inflammatory diseases associated with CD20-expressing cells.
Patent NZ-577936-A (NZ)
Title: Agents for controlling parasites on animals
Inventor: SIRINYAN KIRKOR
IPC: A01N47/02
Filed: 2007-12-14
Abstract: Disclosed is a composition for controlling parasites on animals, which comprises an N-arylpyrazole such as fipronil or 5-amino-4-trifluoromethylsulphinyl-1-(2,6-dichloro-4-trifluoromethylphenyl)-3-thiocarbamoylpyrazole in a formulation comprising: an aliphatic cyclic carbonate selected from ethylene carbonate or propylene carbonate and mixtures thereof; an aliphatic cyclic or acyclic polyether being an ether derived from a diol having up to 8 carbon atoms (such as diethylene glycol monoethyl ether, diethylene glycol monopropyl ether or dipropylene glycol monopropyl ether), or a 5- or 6-membered cyclic ether having a ring oxygen and 4 or 5 ring carbon atoms and optionally carrying a alkyl substituent (such as tetrahydrofurfuryl alcohol); and one or more esters of a dihydric or trihydric alcohol having up to three carbon atoms with organic fatty acids having 6 to 18 carbon atoms.
Patent NZ-578146-A (NZ)
Title: A thermally broken frame
Inventor: HAWKINS TAMOR PETER
IPC: E06B3/273
Filed: 2008-09-18
Abstract: Disclosed is a frame for carrying at least two spaced apart panels, where one of the panels includes a panel frame at part of its periphery. The frame includes a first insulating member defined by an upstanding wall portion extending inwardly between the panels to thermally shield the panel frame. The first insulating member extends to or beyond an innermost extent of the panel frame. (62) Divided Out of 571332
Patent NZ-586636-A (NZ)
Title: Process for production of radioactive-fluorine-labeled organic compound
Inventor: KUROSAKI FUMIE
IPC: C07B61/00
Filed: 2008-12-16
Abstract: A process for producing a radioactive fluorine-labelled organic compound, which comprises subjecting a compound represented by the following formula (1), wherein R1 is a straight or branched alkyl chain with 1-10 carbon atoms or an aromatic substituent, R2 is a straight or branched haloalkylsulfonic acid substituent with 1-10 carbon atoms, a straight or branched alkylsulfonic acid substituent with 1-10 carbon atoms, a fluorosulfonic acid substituent or an aromatic sulfonic acid substituent, and R3 is a protective group, to a heating step in an inert organic solvent in a presence of a phase transfer catalyst, 18F ions and potassium ions, so as to obtain a compound represented by the following formula (2), wherein R1 is a straight or branched alkyl chain with 1-10 carbon atoms or an aromatic substituent, R3 is a protective group, in which the heating step is conducted at a heating temperature of 40-90 Deg. C, the phase transfer catalyst is contained in the inert organic solvent at a concentration of not less than 70 mmol/L, potassium ions are contained in the inert organic solvent at a concentration of not less than 27 mmol/L, and the phase transfer catalyst is used in a molar ratio of not less than 0.7 relative to the compound represented by the formula (1).
Patent NZ-586737-A (NZ)
Title: Compositions and methods of detecting tiabs
Inventor: BIHAIN BERNARD
IPC: G01N33/53
Filed: 2008-12-15
Abstract: Disclosed is a method for detecting the presence, risk or stage of development of a cancer in a subject, the method comprising: a) contacting in vitro: (i) a sample from the subject, said sample being previously treated by heating between 36°C and 60°C to activate a Transcription Infidelity Antibody (TIAB), with (ii) a polypeptide comprising the sequence of an aberrant protein domain created by transcription infidelity gap or insertion, said sequence being selected from the group consisting of SEQ lD NOs: 1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14, 15, 44, 57, 80, 532, 581, 847, 864, 911, 1063, 1075, 1079, 1098, 1270, 1276, 1323, 1330, 1336, 1373, 1380, 1396, 1413, 1451, 1457, 1499, 1699, 1757,1769,1770,1810,1864, 1972 and 2119 b) determining the formation of a complex between said polypeptide and said TIAB antibody present in said sample; c) comparing the level of said TIAB complex formation in said sample to a reference level; wherein an increase in the level of TIAB complex formation in said sample as compared to the reference level is an indication of the presence, risk or stage of development of a cancer.
Patent NZ-589168-A (NZ)
Title: Substituted 2-phenyl-pyridine derivatives
Inventor: CAROFF EVA
IPC: A61K31/44
Filed: 2009-04-09
Abstract: The disclosure relates to substituted 2-phenyl-pyrimidine derivatives of formula (I), wherein the variables are as defined in the specification. These compounds of formula (I) are suitable for use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.
Patent NZ-592704-A (NZ)
Title: Lyophilized recombinant von willebrand factor (rVWF) formulation comprising buffering agents, amino acids, stabilising agents and surfactants
Inventor: SCHNECKER KURT
IPC: A61K38/16
Filed: 2009-10-21
Abstract: A stable lyophilized pharmaceutical formulation of a recombinant von Willebrand Factor (rVWF) comprising: (a) a rVWF; (b) one or more buffering agents; (c) one or more amino acids; (d) one or more stabilizing agents; and (e) one or more surfactants; said rVWF comprising a polypeptide selected from the group consisting of: a) the amino acid sequence set out in SEQ ID NO: 3; b) a biologically active analog, fragment or variant of a); c) a polypeptide encoded by the polynucleotide set out in SEQ ID NO: 1; d) a biologically active analog, fragment or variant of c); and e) a polypeptide encoded by a polynucleotide that hybridizes to the polynucleotide set out in SEQ ID NO: 1 under moderately stringent hybridization conditions; said buffer is comprising of a pH buffering agent in a range of about 0.1 mM to about 500 mM and said pH is in a range of about 2.0 to about 12.0; said amino acid is at a concentration of about 1 to about 500 mM; said stabilizing agent is at a concentration of about 0.1 to about 1000 mM; and said surfactant is at a concentration of about 0.01 g/L to about 0.5 g/L.
Patent NZ-597261-A (NZ)
Title: Patient-adapted and improved orthopedic implants, designs and related tools
Inventor: CHAO NAM
IPC: A61F2/30
Filed: 2010-06-23
Abstract: 597261 Disclosed is a tibial implant for knee arthroplasty and a method of manufacturing the implant with the implant design measurements modified to conform to the patient to provide an improved implant. The tibial implant comprises a medial tibial insert comprising (i) a substantially planar inner surface for engaging a medial tibial tray face and (ii) an articular surface comprising an articular surface plateau and disposed therein a curved portion for opposing an articular surface of a medial femoral condyle. The implant further comprises a lateral tibial insert comprising (i) a substantially planar inner surface for engaging a lateral tibial tray face and (ii) an articular surface comprising an articular surface plateau and disposed therein a curved portion for opposing an articular surface of a lateral femoral condyle. The distance from the inner surface to the articular surface of the medial tibial insert is different from the distance from the inner surface to the articular surface of the lateral tibial insert. The articular surface of the medial tibial insert, the articular surface of the lateral tibial insert, or both, includes patient-adapted sagittal radii or curvature. The minimum, average and maximum distances from the inner surface to the articular surface of the medial tibial insert are substantially different from the minimum, average and maximum distances from the inner surface to the articular surface of the lateral tibial insert respectively.
Patent NZ-597669-A (NZ)
Title: Wall mount for mounting a tablet device to be biased against a surface
Inventor: CHANDLER KENNETH COUPLAND
IPC: F16M13/02
Filed: 2012-01-18
Abstract: A mount (1) is disclosed to be used for retaining a tablet device against a surface. The mount (1) includes a body (5) with a mounting surface portion (3) configured to be mounted against the surface having an upper edge (9). The body (5) also includes an outer face (2) with an upper edge of the outer face forming a first lip (6). The first lip (6) and the upper edge (9) of the mounting surface portion (3) are configured to bias the tablet device towards the surface such that the tablet device contacts the surface.
Patent NZ-601374-A (NZ)
Title: Stabilized antibody-containing liquid formulations
Inventor: IGAWA TOMOYUKI
IPC: A61K47/26
Filed: 2011-01-20
Abstract: Disclosed is a stable antibody-comprising formulation comprising basic amino acid-aspartate or basic amino acid-glutamate, wherein the antibody has been modified to have an isoelectric point (pI) of 5 to 8.
Patent NZ-603828-A (NZ)
Title: Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
Inventor: NABETA KIICHIRO
IPC: A61P29/00
Filed: 2011-04-29
Abstract: Disclosed are non-aqueous taxane pro-emulsion formulations are provided. Pro-emulsion formulations of embodiments of the invention include a taxane, an oil component, a surfactant component and, optionally, a non-aqueous solvent component. Also provided are methods of making and using the pro-emulsion formulations, as well as kits that include the pro-emulsion formulations. Further disclosed is a non-aqueous docetaxel liquid pro-emulsion formulation comprising: an anhydrous docetaxel or a hydrate thereof in an amount ranging from 0.1 to 5% w/w; an oil component in an amount ranging from 0.3 to 5% w/w; an organic acid component; a surfactant component, and a non-aqueous solvent component selected from the group consisting of polyethylene glycols in an amount ranging from 15 to 65% w/w; where the docetaxel liquid pro-emulsion formulation is suitable for parenteral administration to a subject, where the formulation does not include ethanol or isopropanol; and where the amounts of the docetaxel and oil components differ by 50% w/w or less.
Patent NZ-605113-A (NZ)
Title: A tree harvesting vehicle and a method of harvesting trees
Inventor: KELLY NIGEL JOSEPH
IPC: A01G23/091
Filed: 2009-07-15
Abstract: 605113 A tree harvesting vehicle (1) with a winch mounted to the chassis is disclosed. The winch us used to stabilise the position of the vehicle on a slope while harvesting trees, and assist the vehicle up and down the slope using a cable (20) attached to an anchor point (21). Also disclosed is a method of tree harvesting on a slope using the vehicle as well as an additional winch (23) and cable (24). The vehicle fells the trees, puts them into piles (22) and the additional winch (23) is used to haul them up the slope. Minor variations where the trees are hand felled for example are also disclosed.
Patent NZ-607268-A (NZ)
Title: Hand rail and kick plate assembly
IPC: E04G21/32
Filed: 2013-02-18
Abstract: A hand rail and kick plate assembly 10 when used in a platform, walkway or ramp structure has a plurality of hand rails, a plurality of kick plates, and posts 28 connected to a deck of the structure. The posts support the hand rails and kick plates in elevated positions from the deck. The support by the posts is provided by respective brackets 40, 42. The hand rails, kick plates and posts are prefabricated offsite so as to be dimensioned to enable their interconnection on-site to form the assembly without altering their dimensions by use of cutting tools. The support by the posts to the hand rails is provided by brackets which include a substantially L-shaped rod 40.
Patent NZ-608695-A (NZ)
Title: Compositions and methods for the prevention and treatment of cancer
Inventor: SANTAMARIA PERE
IPC: A61P35/00
Filed: 2011-11-11
Abstract: Disclosed is a use of from about 10 to about 500 tumour-antigen/MHC/co-stimulatory molecule complexes operatively coupled to a nanoparticle having a diameter of about 1 to about 100 nm in an amount sufficient to expand a population of antigen-specific T cells in the manufacture of a medicament for the treatment of a tumour or cancer wherein the nanoparticle comprises a metal or metal oxide core.
Patent NZ-613505-A (NZ)
Title: Methods and components for thermal energy storage
Inventor: DUCHEYNE WOUTER
IPC: F28D20/00
Filed: 2012-01-24
Abstract: Method to store or increase the energy content of a reaction mixture by means of an endothermic condensation reaction is disclosed. The reaction mixture comprises an inorganic oxoacid compound and/or its salt and water. The reaction is enabled by the heat input from a heat source distinct from the reaction mixture. The inorganic oxoacid compound and/or its salt can be an oxoacid of nitrogen, sulphur or phosphorus, or its corresponding salt. Further disclosed is a system for capturing or storing energy, comprising capture means for capturing energy and storage means for storing captured energy. The capture and storage means comprise at least one reaction vessel at least partially filled with a reaction mixture comprising an inorganic oxoacid compound and/or its salt and water, suitable for having an endothermic condensation reaction performed on the reaction mixture, and comprising a heating element in thermal communication with the vessel.
Patent NZ-614796-A (NZ)
Title: Optical polarimetric imaging
Inventor: AHARON OFIR
IPC: G01N33/483
Filed: 2012-01-31
Abstract: A method for probing morphology of a tissue surface using a system is disclosed. The system includes a light source (12), a polarizer (18), an analyser, and a camera (2) with a plurality of picture elements. The method illuminates the tissue surface with incident light through the polarizer (18). The camera (2) may capture through the analyser, scattered light from the tissue surface in a continuous sequence of image frames. The process of changing at the same time respective polarization states of the incident light from the light source by varying the polarizer (18) and of the scattered light from the tissue surface by varying the analyser. During the capture, for a picture element of the camera (2), a varying intensity signal of the scattered light is detected responsive to the varying polarization state. The analysing procedure includes determining an average of contrasts between frames of the varying intensity signal.
Patent NZ-709426-A (NZ)
Title: Catheter with markings to facilitate alignment
Inventor: BEASLEY JIM C
IPC: A61M25/01
Filed: 2013-12-31
Abstract: The present invention seeks to reduce the risk of catheter misalignment for successive intravascular interventions. A first, pre-dilation catheter having a first shaft includes a first distal portion adapted for positioning at the treatment area and a first proximal portion including a first marking at a first location. A second, dilation catheter includes a second shaft including a second distal portion is adapted for positioning at the treatment area and a second proximal portion including a second marking at a second location substantially matching a first location of the first marking.
Patent NZ-717864-A (NZ)
Title: Substituted quinolizine derivatives useful as hiv integrase inhibitors
Inventor: STAMFORD ANDREW
IPC: C07D455/04
Filed: 2014-09-26
Abstract: The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R1, R2, R3, R4, R5, R9 and R10 are as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.
Patent NZ-718163-A (NZ)
Title: Extended-release formulation for reducing the frequency of urination and method of use thereof
Inventor: DILL DAVID A
IPC: A61P7/10
Filed: 2013-03-13
Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising zolpidem and one or moren analgesic agents formulated in for oral administration. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release.
Patent NZ-722252-A (NZ)
Title: Hydrophilic antibody-drug conjugates
Inventor: DORONINA SVETLANA
IPC: A61K38/08
Filed: 2015-02-17
Abstract: This application is directed to hydrophilic linkers of formula (I) below and antibody drug conjugates comprising said linkers and auristatin. The conjugates described have higher drug loading while maintaining other favourable pharmacokinetic properties.
Patent NZ-729015-A (NZ)
Title: A teatcup
Inventor: APPELQUIST JOHANNA
IPC: A01J5/02
Filed: 2015-12-14
Abstract: A teatcup comprises a sleeve (2), a teacup liner (3) provided in the sleeve, and a milk receptacle (7) comprising a milk space (8). An inlet channel (9) extends between an inner space (5) of the teatcup liner and the milk space for conveying milk from a teat into the milk space. An outlet channel (10) extends from the milk space and is connectable to a milk conduit (11) for conveying the milk in a milk flow from the milk space. A gas supply channel (12) conveys a gas into the milk space for promoting the milk flow. The gas supply channel has an inlet (13) communicating with a gas source, and an outlet (14) into the milk space. The milk space is partly delimited by a side wall (21). The gas supply channel extends within the side wall and along a surface of the side wall. A controlled flow of gas contributes to an efficient and uniform milk flow and low vacuum variations.
Patent NZ-738524-A (NZ)
Title: Pharmaceutical formulations comprising rilpivirine hydrochloride, tenofovir alafenamide hemifumarate, and emtricitabine
Inventor: SPERGER DIANA
IPC: A61K31/513
Filed: 2016-06-28
Abstract: The invention provides a multilayer tablet comprising rilpivirine hydrochloride, tenofovir alafenamide hemifumarate, and emtricitabine. The invention is particularly useful for the treatment of an HIV infection.
Patent NZ-738862-A (NZ)
Title: Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders
Inventor: BLACKBURN ANTHONY C
IPC: C07D209/94
Filed: 2016-06-21
Abstract: The present invention relates to, inter alia, a novel crystalline free- plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the L- arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy) -l,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) in the treatment of SIPI receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditionscharacterized byan underlying defect in the vascular integrity or that are associated with angiogenesis such as may be pathologic(e.g.,as may occur in inflammation, tumor development, and atherosclerosis).
Patent NZ-748101-A (NZ)
Title: Stable liquid pharmaceutical preparation
Inventor: LEE JOON WON
IPC: A61K9/08
Filed: 2017-06-28
Abstract: A stable liquid pharmaceutical preparation according to the present invention contains: the antibody infliximab; a surfactant; a sugar or a derivative thereof; and a buffer comprising acetate or histidine. The stable liquid pharmaceutical preparation according to the present invention has low viscosity while containing a high amount of the antibody, has excellent long-term storage stability on the basis of excellent stability under accelerated conditions and extreme conditions, and can be administered subcutaneously.